INMUNE BIO INC. Grants Receivable
INMUNE BIO INC. (INMB) had Grants Receivable of $2.00 million as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Nontrade Receivables › Nontrade Receivables, Unclassified
us-gaap:GrantsReceivable · last filed 2025-08-07
- 2025-06-30: Grants Receivable $2.00M.
- 2022-09-30: Grants Receivable $0.00.
- 2022-06-30: Grants Receivable $0.00.
- 2022-03-31: Grants Receivable $0.00.
| Period end | Grants Receivable | Grants Receivable as first filed |
|---|---|---|
| 2025-06-30 | $2.00M 10-Q · filed 2025-08-07 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $100.00K 10-Q · filed 2022-05-05 | $300.00K 10-K · filed 2022-03-03 |
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $100.00K 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $500.00K 10-K · filed 2023-03-02 | $150.00K 10-K · filed 2021-03-04 |
| 2020-09-30 | $2.90M 10-Q · filed 2024-10-31 | $150.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $300.00K 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2020-08-05 |
| 2020-03-31 | $300.00K 10-Q · filed 2021-05-05 | $0.00 10-Q · filed 2020-05-14 |
| 2019-12-31 | $850.00K 10-K · filed 2021-03-04 | |
| 2019-09-30 | $600.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $600.00K 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $600.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |